Decades of improvement in drug discovery technology have failed to improve productivity, and with the patent cliff now at hand, some pharma firms are adopting a back-to-basics approach. When it comes to getting back to basics, Traditional Chinese Medicine is "about as low-tech as it comes," said David Kolb, founder and CEO of Insero Health Inc.